🚀 VC round data is live in beta, check it out!
Hangzhou Tigermed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hangzhou Tigermed and similar public comparables like Laurus Labs, Fortis Healthcare, Sonic Healthcare, Repligen and more.
Hangzhou Tigermed Overview
About Hangzhou Tigermed
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's offered services include bioanalytical, medical writing, biostatistical analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Founded
2004
HQ
Employees
10.2K
Website
Financials (LTM)
EV
$7B
Hangzhou Tigermed Financials
Hangzhou Tigermed reported last 12-month revenue of $1B and EBITDA of $173M.
In the same LTM period, Hangzhou Tigermed generated $299M in gross profit, $173M in EBITDA, and $136M in net income.
Revenue (LTM)
Hangzhou Tigermed P&L
In the most recent fiscal year, Hangzhou Tigermed reported revenue of $1B and EBITDA of $208M.
Hangzhou Tigermed expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $299M | XXX | $275M | XXX | XXX | XXX |
| Gross Margin | 29% | XXX | 27% | XXX | XXX | XXX |
| EBITDA | $173M | XXX | $208M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $136M | XXX | $130M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hangzhou Tigermed Stock Performance
Hangzhou Tigermed has current market cap of $7B, and enterprise value of $7B.
Market Cap Evolution
Hangzhou Tigermed's stock price is $8.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $7B | 0.0% | XXX | XXX | XXX | $0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHangzhou Tigermed Valuation Multiples
Hangzhou Tigermed trades at 6.7x EV/Revenue multiple, and 39.8x EV/EBITDA.
EV / Revenue (LTM)
Hangzhou Tigermed Financial Valuation Multiples
As of April 19, 2026, Hangzhou Tigermed has market cap of $7B and EV of $7B.
Equity research analysts estimate Hangzhou Tigermed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hangzhou Tigermed has a P/E ratio of 50.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | 39.8x | XXX | 33.1x | XXX | XXX | XXX |
| EV/EBIT | 60.4x | XXX | 70.5x | XXX | XXX | XXX |
| EV/Gross Profit | 23.0x | XXX | 25.1x | XXX | XXX | XXX |
| P/E | 50.8x | XXX | 53.1x | XXX | XXX | XXX |
| EV/FCF | 61.3x | XXX | 52.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hangzhou Tigermed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hangzhou Tigermed Margins & Growth Rates
Hangzhou Tigermed's revenue in the last 12 month grew by 14%.
Hangzhou Tigermed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Hangzhou Tigermed's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hangzhou Tigermed's rule of X is 49% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Hangzhou Tigermed Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | (3%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hangzhou Tigermed Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hangzhou Tigermed | XXX | XXX | XXX | XXX | XXX | XXX |
| Laurus Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Fortis Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Repligen | XXX | XXX | XXX | XXX | XXX | XXX |
| Dixon Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hangzhou Tigermed M&A Activity
Hangzhou Tigermed acquired XXX companies to date.
Last acquisition by Hangzhou Tigermed was on XXXXXXXX, XXXXX. Hangzhou Tigermed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hangzhou Tigermed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHangzhou Tigermed Investment Activity
Hangzhou Tigermed invested in XXX companies to date.
Hangzhou Tigermed made its latest investment on XXXXXXXX, XXXXX. Hangzhou Tigermed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hangzhou Tigermed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hangzhou Tigermed
| When was Hangzhou Tigermed founded? | Hangzhou Tigermed was founded in 2004. |
| Where is Hangzhou Tigermed headquartered? | Hangzhou Tigermed is headquartered in China. |
| How many employees does Hangzhou Tigermed have? | As of today, Hangzhou Tigermed has over 10K employees. |
| Is Hangzhou Tigermed publicly listed? | Yes, Hangzhou Tigermed is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Hangzhou Tigermed? | Hangzhou Tigermed trades under 300347 ticker. |
| When did Hangzhou Tigermed go public? | Hangzhou Tigermed went public in 2012. |
| Who are competitors of Hangzhou Tigermed? | Hangzhou Tigermed main competitors are Laurus Labs, Fortis Healthcare, Sonic Healthcare, Repligen. |
| What is the current market cap of Hangzhou Tigermed? | Hangzhou Tigermed's current market cap is $7B. |
| What is the current revenue of Hangzhou Tigermed? | Hangzhou Tigermed's last 12 months revenue is $1B. |
| What is the current revenue growth of Hangzhou Tigermed? | Hangzhou Tigermed revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Hangzhou Tigermed? | Current revenue multiple of Hangzhou Tigermed is 6.7x. |
| Is Hangzhou Tigermed profitable? | Yes, Hangzhou Tigermed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hangzhou Tigermed? | Hangzhou Tigermed's last 12 months EBITDA is $173M. |
| What is Hangzhou Tigermed's EBITDA margin? | Hangzhou Tigermed's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Hangzhou Tigermed? | Current EBITDA multiple of Hangzhou Tigermed is 39.8x. |
| What is the current FCF of Hangzhou Tigermed? | Hangzhou Tigermed's last 12 months FCF is $112M. |
| What is Hangzhou Tigermed's FCF margin? | Hangzhou Tigermed's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Hangzhou Tigermed? | Current FCF multiple of Hangzhou Tigermed is 61.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.